Dendreon licenses anticoagulant program to Nuvelo
Executive Summary
Nuvelo Inc. (the 2003 merger of Variagenics with Hyseq Pharma) has licensed worldwide development and marketing rights to Dendreon Corp.'s (developing cancer vaccines and treatments) recombinant nematode anticoagulant proteins, including the Phase II drug candidate rNAPc2.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice